CME and CFTC Lock Horns Over On-Chain Perpetual Futures

The CME Group, the largest derivatives exchange operator in the U.S., has found itself at odds with its regulator, the Commodity Futures Trading Commission (CFTC), over the agency's decision to allow the listing of crypto perpetual futures products. This move has been met with resistance from the CME, which argues that these products are, in fact, swaps and not futures, and that the CFTC has misapplied the law by approving them without proper consideration of the implications. The CME claims that perpetual futures, which are designed to allow traders to take a position on an asset's price without an expiration date, are detrimental to its traditional futures products and has filed a lawsuit against the CFTC to block their approval. The dispute has significant implications for the U.S. approach to the rapidly growing market for perpetual futures, with non-U.S. volumes reportedly reaching $60 trillion in the last year. The CFTC's decision to allow these products has been seen as a departure from its traditional stance, and the agency's chairman, Mike Selig, has been accused of not following proper protocol in approving the products. The CME's lawsuit argues that the CFTC's actions are harmful to its business and that the agency has failed to consider the potential consequences of its decision. The case is currently awaiting federal court action and is being closely watched by market participants and regulators alike. The outcome of the dispute is likely to have far-reaching implications for the U.S. derivatives market and the development of on-chain perpetual futures products.